With nearly 7400 new cases coming every day, HIV infection has become devastating in last a few years. Current therapy involves a combination of at least three antiretroviral (ARV) drugs, used to extend the lifespan. But, the treatment requires daily oral dosing, and chronic oral dosing has significant complications that arise from the high pill burden experienced by many patients with varying conditions leading to non-adherence to therapies.
Nanotechnology-based drug system promises to improve the situation and offer unique advantages like enhancement of bioavailability, water solubility, stability, and targeting ability of ARV drugs. A healthy volunteer trial, conducted by the collaborative nanomedicine research program examined the use of nanotechnology to improve the delivery of drugs to HIV patients. The results were from two trials which are the first to use orally dosed…
